<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632345</url>
  </required_header>
  <id_info>
    <org_study_id>1439-007</org_study_id>
    <secondary_id>MK-1439-007</secondary_id>
    <secondary_id>2012-001573-93</secondary_id>
    <nct_id>NCT01632345</nct_id>
  </id_info>
  <brief_title>A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)</brief_title>
  <official_title>Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis tested in this study is that doravirine (MK-1439) at the final dose selected
      is superior to efavirenz, each given in combination with TRUVADA®, as measured by the
      percentage of participants with CNS events by Week 8. If superiority is established at Week
      8, the same hypothesis will be tested for Week 24.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part I - Dose-Ranging. Part I will evaluate the (1) safety and tolerability and (2) efficacy
      (antiretroviral activity) of 4 doses of doravirine compared with efavirenz, when each is
      given in combination with TRUVADA® for at least 24 weeks in approximately 200 participants. A
      single dose of doravirine will be selected for further study after all participants complete
      the Week 24 visit in Part I. Participants receiving any dose of doravirine in Part I will be
      switched to the selected doravirine dose and continue in the study for up to 96 weeks, but
      will not be randomized to Part II.

      Part II - Selected Dose. Part II will be initiated after the doravirine dose has been
      selected as indicated above for Part 1. Approximately 120 additional participants will be
      randomized in 1:1 ratio to the selected dose of doravirine or efavirenz, each in combination
      with TRUVADA® for 96 weeks of blinded treatment. Part II will evaluate the safety of the
      selected dose compared with efavirenz, particularly with regard to central nervous system
      (CNS) adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2012</start_date>
  <completion_date type="Actual">March 21, 2016</completion_date>
  <primary_completion_date type="Actual">December 3, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who discontinued therapy due to an AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Weeks 0-24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR's product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was assessed for Weeks 0-24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 8 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 24 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-24.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA) &lt; 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy.This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 48</time_frame>
    <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 96</time_frame>
    <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay.The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This secondary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 48</time_frame>
    <description>Evaluation of the antiretroviral activity of doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA for 24 weeks, as measured by the percentage of participants with HIV-1 RNA &lt;200 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. This primary outcome was analyzed for RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Week 96</time_frame>
    <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-96. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Evaluation of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, and 200 mg), compared with participants receiving efavirenz 600 mg. The Observed Failure (OF) approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Assessment of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Assessment of the change from baseline in the CD4 count at Week 48 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Baseline, Week 96</time_frame>
    <description>A secondary endpoint in Part I/II combined was the change from baseline in the CD4 count at Week 96 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 48 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</measure>
    <time_frame>Up to Week 96</time_frame>
    <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 96 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-96.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">342</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Doravirine 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doravirine 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doravirine 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doravirine</intervention_name>
    <description>Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.</description>
    <arm_group_label>Doravirine 25 mg</arm_group_label>
    <arm_group_label>Doravirine 50 mg</arm_group_label>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
    <arm_group_label>Doravirine 200 mg</arm_group_label>
    <other_name>MK-1439</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRUVADA®</intervention_name>
    <description>Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks</description>
    <arm_group_label>Doravirine 25 mg</arm_group_label>
    <arm_group_label>Doravirine 50 mg</arm_group_label>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
    <arm_group_label>Doravirine 200 mg</arm_group_label>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Doravirine</intervention_name>
    <description>Placebo tablets matching doravirine</description>
    <arm_group_label>Doravirine 25 mg</arm_group_label>
    <arm_group_label>Doravirine 50 mg</arm_group_label>
    <arm_group_label>Doravirine 100 mg</arm_group_label>
    <arm_group_label>Doravirine 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Efavirenz</intervention_name>
    <description>Placebo tablets matching efavirenz</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive

          -  No previous use of antiretroviral therapy (ART)

          -  No signs of active pulmonary disease within 45 days before the start of study
             treatment

          -  Clinically stable with no signs or symptoms of acute infection

          -  No change in clinical status or chronic medications for at least 2 weeks before the
             start of study treatment

          -  Participants of reproductive potential agree to remain abstinent in line with their
             preferred and usual lifestyle or use (or have their partner use) 2 acceptable methods
             of birth control throughout the study and for 12 weeks post study.

          -  Participants not of reproductive potential, not sexually active, whose current
             partner(s) is not of reproductive potential, or whose sexual activity is exclusively
             homosexual are eligible without requiring the use of contraception.

        Exclusion Criteria:

          -  Males planning to impregnate or provide sperm donation for the duration of the study
             plus an additional 12 weeks. Females pregnant or breast-feeding or expecting to
             conceive or donate eggs for the duration of the study plus an additional 12 weeks.

          -  Received any approved or experimental antiretroviral agents or is anticipated to
             receive such medications during the study.

          -  Use of any immunomodulators or immunosuppressive therapy within one month before the
             study. Short courses of corticosteroids (e.g., for asthma exacerbation) are allowed.

          -  Treatment for a viral infection other than HIV, such as hepatitis B, with an agent
             that is active against HIV

          -  HIV resistance to emtricitabine, tenofovir disoproxil fumarate, and/or efavirenz.

          -  History of renal or urinary obstructive disease or requires dialysis

          -  Active Hepatitis C virus (HCV) or Hepatitis B virus (HBV) co-infection

          -  History of alcohol or other substance abuse

          -  Participation in a study with an investigational compound/device within one month or
             is anticipating to participate in such a study during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2012</study_first_posted>
  <results_first_submitted>November 16, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>210 participants were randomized to Part I and 132 participants were randomized to Part II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part I: Doravirine 25 mg</title>
          <description>Doravirine 25 mg once daily plus TRUVADA once daily in Part I</description>
        </group>
        <group group_id="P2">
          <title>Part I: Doravirine 50 mg</title>
          <description>Doravirine 50 mg once daily plus TRUVADA once daily in Part I</description>
        </group>
        <group group_id="P3">
          <title>Part I: Doravirine 100 mg</title>
          <description>Doravirine 100 mg once daily plus TRUVADA once daily in Part I</description>
        </group>
        <group group_id="P4">
          <title>Part I: Doravirine 200 mg</title>
          <description>Doravirine 200 mg once daily plus TRUVADA once daily in Part I</description>
        </group>
        <group group_id="P5">
          <title>Part I: Efavirenz 600 mg</title>
          <description>Efavirenz 600 mg once daily plus TRUVADA once daily in Part I</description>
        </group>
        <group group_id="P6">
          <title>Part II: Doravirine 100 mg</title>
          <description>Doravirine 100 mg once daily plus TRUVADA once daily in Part II</description>
        </group>
        <group group_id="P7">
          <title>Part II: Efavirenz 600 mg</title>
          <description>Efavirenz 600 mg once daily plus TRUVADA once daily in Part II</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Participants</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="66"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="66"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment: Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="0">Participants in Part II did not participate in Part I.</participants>
                <participants group_id="P7" count="0">Participants in Part II did not participate in Part I.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment: Part II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants in Part I did not continue in Part II.</participants>
                <participants group_id="P2" count="0">Participants in Part I did not continue in Part II.</participants>
                <participants group_id="P3" count="0">Participants in Part I did not continue in Part II.</participants>
                <participants group_id="P4" count="0">Participants in Part I did not continue in Part II.</participants>
                <participants group_id="P5" count="0">Participants in Part I did not continue in Part II.</participants>
                <participants group_id="P6" count="66">66 new participants enrolled at 100 mg dose in Part II.</participants>
                <participants group_id="P7" count="66">66 new participants enrolled at efavirenz treatment in Part II.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="66"/>
                <participants group_id="P7" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="55"/>
                <participants group_id="P7" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Treated participants randomized to doravirine or efavirenz using an interactive voice response system (IVRS)</population>
      <group_list>
        <group group_id="B1">
          <title>Doravirine 25 mg: Part I/II Combined</title>
          <description>Doravirine 25 mg once daily plus TRUVADA once daily</description>
        </group>
        <group group_id="B2">
          <title>Doravirine 50 mg Part I/II Combined</title>
          <description>Doravirine 50 mg once daily plus TRUVADA once daily</description>
        </group>
        <group group_id="B3">
          <title>Doravirine 100 mg: Part I/II Combined</title>
          <description>Doravirine 100 mg once daily plus TRUVADA once daily</description>
        </group>
        <group group_id="B4">
          <title>Doravirine 200 mg: Part I/II Combined</title>
          <description>Doravirine 200 mg once daily plus TRUVADA once daily</description>
        </group>
        <group group_id="B5">
          <title>Efavirenz 600 mg: Part I/II Combined</title>
          <description>Efavirenz 600 mg once daily plus TRUVADA once daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="108"/>
            <count group_id="B6" value="340"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="13.42"/>
                    <measurement group_id="B2" value="38.3" spread="10.71"/>
                    <measurement group_id="B3" value="36.8" spread="11.31"/>
                    <measurement group_id="B4" value="34.4" spread="8.85"/>
                    <measurement group_id="B5" value="35.2" spread="9.08"/>
                    <measurement group_id="B6" value="36.4" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="101"/>
                    <measurement group_id="B6" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
        <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-24.</description>
        <time_frame>Up to Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in Part I.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg: Part I</title>
            <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 50 mg: Part I</title>
            <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O3">
            <title>Doravirine 100 mg : Part I</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O4">
            <title>Doravirine 200 mg: Part I</title>
            <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O5">
            <title>Efavirenz 600 mg: Part I</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
          <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-24.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in Part I.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="76.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="93.0" lower_limit="80.9" upper_limit="98.5"/>
                    <measurement group_id="O3" value="71.4" lower_limit="55.4" upper_limit="84.3"/>
                    <measurement group_id="O4" value="85.4" lower_limit="70.8" upper_limit="94.4"/>
                    <measurement group_id="O5" value="83.3" lower_limit="68.6" upper_limit="93.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>22.4</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>9.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>24.9</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.9</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.5</ci_lower_limit>
            <ci_upper_limit>18.4</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
        <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who discontinued therapy due to an AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Weeks 0-24.</description>
        <time_frame>Up to Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in Part I.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg: Part I</title>
            <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 50 mg: Part I</title>
            <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O3">
            <title>Doravirine 100 mg: Part I</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O4">
            <title>Doravirine 200 mg: Part I</title>
            <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O5">
            <title>Efavirenz 600 mg: Part I</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Therapy Due to AEs in Weeks 0-24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
          <description>Assessment of the percentage of participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, or 200 mg), compared with participants receiving efavirenz 600 mg, who discontinued therapy due to an AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group who discontinued therapy due to an AE was primarily assessed for Weeks 0-24.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in Part I.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="7.0" lower_limit="1.5" upper_limit="19.1"/>
                    <measurement group_id="O3" value="2.4" lower_limit="0.1" upper_limit="12.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="8.6"/>
                    <measurement group_id="O5" value="4.8" lower_limit="0.6" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.7</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was assessed for Weeks 0-24.</description>
        <time_frame>Up to Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 1 AE in Weeks 0-24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 24 weeks of treatment. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR’s product, whether or not considered related to the use of the product.The percentage of participants in any treatment group with at least 1 AE was assessed for Weeks 0-24.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="65.7" upper_limit="82.8"/>
                    <measurement group_id="O2" value="85.2" lower_limit="77.1" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-10.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.9</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 8 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-8.</description>
        <time_frame>Up to Week 8</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CNS Events by Week 8: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 8 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-8.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="16.4" upper_limit="33.3"/>
                    <measurement group_id="O2" value="44.4" lower_limit="34.9" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Superiority analysis</p_value_desc>
            <method>Miettinen and Nurminen method</method>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-20.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.4</ci_lower_limit>
            <ci_upper_limit>-7.8</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 24 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-24.</description>
        <time_frame>Up to Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CNS Events by Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had CNS events over 24 weeks of treatment. CNS events were pooled and evaluated as pre-specified by the protocol (depression, nightmare, confusional state, suicidal ideation, nervous system disorder, psychotic disorder, abnormal dreams, suicide attempt, acute psychosis, delirium, depressed level of consciousness, hallucination, hallucination auditory, hallucination visual, completed suicide, suicidal behavior, major depression, depressed mood, depressive symptom, insomnia, disturbance in attention, somnolence, dizziness, or concentration impaired). The percentage of participants in either treatment group with CNS events was assessed over Weeks 0-24.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="18.8" upper_limit="36.2"/>
                    <measurement group_id="O2" value="47.2" lower_limit="37.5" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>Superiority analysis</p_value_desc>
            <method>Miettinen and Nurminen method</method>
            <param_type>Difference (Doravirine - Efavirenz)</param_type>
            <param_value>-20.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.6</ci_lower_limit>
            <ci_upper_limit>-7.5</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA) &lt; 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
        <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy.This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I.</description>
        <time_frame>Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg: Part I</title>
            <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 50 mg: Part I</title>
            <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O3">
            <title>Doravirine 100 mg: Part I</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O4">
            <title>Doravirine 200 mg: Part I</title>
            <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O5">
            <title>Efavirenz 600 mg: Part I</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA) &lt; 40 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
          <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy.This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 24 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="64.4" upper_limit="90.9"/>
                    <measurement group_id="O2" value="74.4" lower_limit="58.8" upper_limit="86.5"/>
                    <measurement group_id="O3" value="71.4" lower_limit="55.4" upper_limit="84.3"/>
                    <measurement group_id="O4" value="80.5" lower_limit="65.1" upper_limit="91.2"/>
                    <measurement group_id="O5" value="64.3" lower_limit="48.0" upper_limit="78.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>34.4</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>10.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>29.1</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>6.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>26.0</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>15.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>34.4</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification of 40 copies/mL. The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 24 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="63.4" upper_limit="81.0"/>
                    <measurement group_id="O2" value="73.1" lower_limit="63.8" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.2</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 48</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 48 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 48 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="68.8" upper_limit="85.2"/>
                    <measurement group_id="O2" value="79.4" lower_limit="70.5" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>9.2</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 96</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 96 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;40 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with HIV-1 RNA &lt;40 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;40 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;40 copies/mL) at 96 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="65.7" upper_limit="82.8"/>
                    <measurement group_id="O2" value="75.9" lower_limit="66.7" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.4</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
        <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay.The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I.</description>
        <time_frame>Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg: Part I</title>
            <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 50 mg: Part I</title>
            <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O3">
            <title>Doravirine 100 mg: Part I</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O4">
            <title>Doravirine 200 mg: Part I</title>
            <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O5">
            <title>Efavirenz 600 mg: Part I</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
          <description>Assessment of the virologic response to doravirine at all studied doses (25 mg, 50 mg, 100 mg, and 200 mg), compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay.The percentage of participants in any treatment group with a virologic response was assessed at Week 24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 24 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="70.2" upper_limit="94.3"/>
                    <measurement group_id="O2" value="83.7" lower_limit="69.3" upper_limit="93.2"/>
                    <measurement group_id="O3" value="92.9" lower_limit="80.5" upper_limit="98.5"/>
                    <measurement group_id="O4" value="90.2" lower_limit="76.9" upper_limit="97.3"/>
                    <measurement group_id="O5" value="81.0" lower_limit="65.9" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>21.5</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>19.8</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>12.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>25.7</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This secondary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 24. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-24. The NC=F approach was used as the primary approach to handle missing data for this analysis of efficacy. This secondary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 24 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="82.3" upper_limit="94.8"/>
                    <measurement group_id="O2" value="87.0" lower_limit="79.2" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>11.7</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Evaluation of the antiretroviral activity of doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA for 24 weeks, as measured by the percentage of participants with HIV-1 RNA &lt;200 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. This primary outcome was analyzed for RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 48</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV RNA (&lt;200 copies/mL) at 48 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Evaluation of the antiretroviral activity of doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA for 24 weeks, as measured by the percentage of participants with HIV-1 RNA &lt;200 copies/mL at Week 48. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. This primary outcome was analyzed for RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV RNA (&lt;200 copies/mL) at 48 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.2" lower_limit="77.1" upper_limit="91.3"/>
                    <measurement group_id="O2" value="85.0" lower_limit="76.9" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>9.9</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-96. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
        <time_frame>Week 96</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 96 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Response (HIV-1 RNA &lt;200 Copies/mL) at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the virologic response to doravirine at 100 mg, compared to efavirenz, each in combination with TRUVADA, as measured by the percentage of participants with plasma HIV-1 RNA &lt;200 copies/mL at Week 96. HIV RNA levels were determined using the Abbott RealTime HIV-1 Assay. The percentage of participants in any treatment group with a virologic response was primarily assessed for Weeks 0-96. The Non-Completer = Failure (NC=F) approach, in which participants who prematurely discontinued assigned treatment for any reason and were considered as failures thereafter, was used as the primary approach to handle missing data this analysis of efficacy. This primary outcome was analyzed for HIV-1 RNA &lt;200 copies/mL in Part I &amp; Part II combined.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of HIV-1 RNA (&lt;200 copies/mL) at 96 weeks of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="70.8" upper_limit="86.8"/>
                    <measurement group_id="O2" value="75.9" lower_limit="66.7" upper_limit="83.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in % response</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
        <description>Evaluation of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, and 200 mg), compared with participants receiving efavirenz 600 mg. The Observed Failure (OF) approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of CD4 cell count at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 25 mg: Part I</title>
            <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O2">
            <title>Doravirine 50 mg: Part I</title>
            <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O3">
            <title>Doravirine 100 mg: Part I</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O4">
            <title>Doravirine 200 mg: Part I</title>
            <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
          <group group_id="O5">
            <title>Efavirenz 600 mg: Part I</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 T Lymphocyte Cell Count at Week 24: Doravirine (All Doses) vs Efavirenz (Part I)</title>
          <description>Evaluation of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at all doses (25 mg, 50 mg, 100 mg, and 200 mg), compared with participants receiving efavirenz 600 mg. The Observed Failure (OF) approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in Part I, and had at least one post-randomization observation for the analysis of CD4 cell count at 24 weeks of study treatment.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.1" lower_limit="115.1" upper_limit="193.1"/>
                    <measurement group_id="O2" value="112.9" lower_limit="74.5" upper_limit="151.2"/>
                    <measurement group_id="O3" value="133.6" lower_limit="100.4" upper_limit="166.8"/>
                    <measurement group_id="O4" value="140.7" lower_limit="95.6" upper_limit="185.7"/>
                    <measurement group_id="O5" value="121.1" lower_limit="73.3" upper_limit="169.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>33.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.1</ci_lower_limit>
            <ci_upper_limit>94.0</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>-8.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.5</ci_lower_limit>
            <ci_upper_limit>51.9</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>12.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-44.6</ci_lower_limit>
            <ci_upper_limit>69.5</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>19.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.1</ci_lower_limit>
            <ci_upper_limit>84.2</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of CD4 cell count at 24 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Week 24: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the change from baseline in the CD4 cell count at Week 24 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for participants who discontinued assigned treatment due to lack of efficacy.</description>
          <population>The analyzed population consisted of all randomized participants who received at least one dose of blinded study treatment in either Part I or Part II, and had at least one post-randomization observation for the analysis of CD4 cell count at 24 weeks of study treatment.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.3" lower_limit="121.7" upper_limit="182.8"/>
                    <measurement group_id="O2" value="146.0" lower_limit="113.1" upper_limit="178.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.2</ci_lower_limit>
            <ci_upper_limit>50.8</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>Assessment of the change from baseline in the CD4 count at Week 48 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>The analyzed population consisted of all randomized subjects who had baseline data, received at least 1 dose of blinded study medication in either Part I or Part II, and had at least 1 post-randomization observation for the analysis of CD4 cell count at 48 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Week 48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>Assessment of the change from baseline in the CD4 count at Week 48 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
          <population>The analyzed population consisted of all randomized subjects who had baseline data, received at least 1 dose of blinded study medication in either Part I or Part II, and had at least 1 post-randomization observation for the analysis of CD4 cell count at 48 weeks of study treatment.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191.9" lower_limit="160.8" upper_limit="223.1"/>
                    <measurement group_id="O2" value="194.5" lower_limit="163.2" upper_limit="225.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.5</ci_lower_limit>
            <ci_upper_limit>41.3</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>A secondary endpoint in Part I/II combined was the change from baseline in the CD4 count at Week 96 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
        <time_frame>Baseline, Week 96</time_frame>
        <population>The analyzed population consisted of all randomized subjects who had baseline data, received at least 1 dose of blinded study medication in either Part I or Part II, and had at least 1 post-randomization observation for the analysis of CD4 cell count at 96 weeks of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Week 96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>A secondary endpoint in Part I/II combined was the change from baseline in the CD4 count at Week 96 in participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg. The OF approach was used to handle missing data, and the Baseline CD4 cell count was carried forward for subjects who discontinued assigned treatment due to lack of efficacy.</description>
          <population>The analyzed population consisted of all randomized subjects who had baseline data, received at least 1 dose of blinded study medication in either Part I or Part II, and had at least 1 post-randomization observation for the analysis of CD4 cell count at 96 weeks of study treatment.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.2" lower_limit="220.0" upper_limit="298.3"/>
                    <measurement group_id="O2" value="263.6" lower_limit="218.1" upper_limit="309.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in CD4 change</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.0</ci_lower_limit>
            <ci_upper_limit>55.1</ci_upper_limit>
            <estimate_desc>A positive value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 48 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-48.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 1 AE in Weeks 0-48: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 48 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-48.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0" lower_limit="79.2" upper_limit="92.7"/>
                    <measurement group_id="O2" value="89.8" lower_limit="82.5" upper_limit="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.7</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
        <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 96 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-96.</description>
        <time_frame>Up to Week 96</time_frame>
        <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
        <group_list>
          <group group_id="O1">
            <title>Doravirine 100 mg: Part I/II (Combined)</title>
            <description>Doravirine 100 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 600 mg: Part I/II (Combined)</title>
            <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in either Part I or Part II</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 1 AE in Weeks 0-96: Doravirine 100 mg vs Efavirenz (Part I &amp; Part II Combined)</title>
          <description>A secondary outcome in Part I/II combined was the percentage of participants receiving doravirine at 100 mg, compared with participants receiving efavirenz 600 mg, who had at least 1 AE over 96 weeks of treatment. The percentage of participants in any treatment group with at least 1 AE was primarily assessed for Weeks 0-96.</description>
          <population>The analyzed population consisted of all randomized participants who received at least 1 dose of study treatment in either Part I or Part II.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="82.5" upper_limit="94.8"/>
                    <measurement group_id="O2" value="96.3" lower_limit="90.8" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.1</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>A negative value would be considered as favoring doravirine over efavirenz.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <desc>All Treated participants randomized to doravirine or efavirenz using an IVRS</desc>
      <group_list>
        <group group_id="E1">
          <title>Doravirine 25 mg (n=40)</title>
          <description>Doravirine 25 mg once daily plus TRUVADA once daily received in Part I</description>
        </group>
        <group group_id="E2">
          <title>Doravirine 50 mg (n=43)</title>
          <description>Doravirine 50 mg once daily plus TRUVADA once daily received in Part I</description>
        </group>
        <group group_id="E3">
          <title>Doravirine 100 mg (n=108)</title>
          <description>Doravirine 100 mg once daily plus TRUVADA once daily received in Part I &amp; Part II (Combined)</description>
        </group>
        <group group_id="E4">
          <title>Doravirine 200 mg (n=41)</title>
          <description>Doravirine 200 mg once daily plus TRUVADA once daily received in Part I</description>
        </group>
        <group group_id="E5">
          <title>Efavirenz 600 mg: Part I (n=108)</title>
          <description>Efavirenz 600 mg once daily plus TRUVADA once daily received in Part I &amp; Part II (Combined)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cryptosporidiosis infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell unclassifiable lymphoma high grade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E5" events="20" subjects_affected="18" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="31" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E5" events="16" subjects_affected="13" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="19" subjects_affected="13" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="10" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="14" subjects_affected="10" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="38" subjects_affected="32" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="27" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E5" events="26" subjects_affected="15" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E5" events="21" subjects_affected="19" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="12" subjects_affected="11" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

